Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

PURPOSE: Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gilbert, Mark R., Wang, Meihua, Aldape, Kenneth D., Stupp, Roger, Hegi, Monika E., Jaeckle, Kurt A., Armstrong, Terri S., Wefel, Jeffrey S., Won, Minhee, Blumenthal, Deborah T., Mahajan, Anita, Schultz, Christopher J., Erridge, Sara, Baumert, Brigitta, Hopkins, Kristen I., Tzuk-Shina, Tzahala, Brown, Paul D., Chakravarti, Arnab, Curran, Walter J., Mehta, Minesh P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3816958/
https://ncbi.nlm.nih.gov/pubmed/24101040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.49.6968
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados